儿童Graves病患者接受卡比马唑治疗时中性粒细胞减少的发生率高于甲巯咪唑
这项回顾性队列研究分析了161例接受甲巯咪唑或卡比马唑治疗的儿童Graves病患者,发现卡比马唑组中性粒细胞减少发生率(50%,20/40)显著高于甲巯咪唑组(16.5%,18/110;p=0.001),且卡比马唑组最低中性粒细胞绝对值更低。作者建议儿童Graves病患者应使用甲巯咪唑治疗,并可能需要频繁监测中性粒细胞绝对值以发现严重粒细胞缺乏症。
要点
- 卡比马唑组中性粒细胞减少发生率50%(20/40)显著高于甲巯咪唑组16.5%(18/110),p=0.001。
- 38例(23.6%)患者在抗甲状腺药物治疗期间出现中性粒细胞减少,其中2例进展为粒细胞缺乏症并接受急诊甲状腺切除术。
- 作者建议儿童Graves病患者应使用甲巯咪唑治疗,并可能需要频繁监测中性粒细胞绝对值。
核心结论
- 卡比马唑治疗下中性粒细胞减少的发生率显著高于甲巯咪唑。
- 作者认为这可能与卡比马唑免疫原性较高有关,建议儿童Graves病患者应使用甲巯咪唑治疗。
- 可能需要频繁测量中性粒细胞绝对值以发现严重粒细胞缺乏症,尽管治疗前中性粒细胞绝对值偏低不一定是对抗甲状腺药物治疗的禁忌。
- 年轻年龄可能与中性粒细胞绝对值降低风险增加相关。
- 需要进一步研究以充分了解儿童Graves病患者中性粒细胞减少的危险因素。
研究设计与样本
- 回顾性队列研究,分析161例接受甲巯咪唑或卡比马唑治疗的儿童Graves病患者的纵向临床和生化数据。
- 纳入标准为游离甲状腺素升高(fT4 >25 pmol/L)、促甲状腺激素抑制(TSH <0.05 mlU/mL)和促甲状腺激素受体抗体升高(TSHRAbs >2.5 IU/L)。
- 中性粒细胞减少定义为中性粒细胞绝对值<1800/µL,粒细胞缺乏症定义为中性粒细胞绝对值<500/µL。
主要发现
- 161例患者中9例在诊断时即有中性粒细胞减少(中性粒细胞绝对值1348/µL ± 250),抗甲状腺药物治疗下未进一步恶化。
- 该亚组诊断时游离三碘甲状腺原氨酸水平(31.45 pmol/L ± 3.99)高于后来发生中性粒细胞减少者(26.29 pmol/L ± 12.96;p=0.07)及治疗前和治疗期间均无中性粒细胞减少者(23.12 pmol/L ± 13.7;p=0.003)。
- 38例患者(23.6%)在接受抗甲状腺药物治疗期间出现中性粒细胞减少(中性粒细胞绝对值1479/µL ± 262),平均发生于551.8天(范围10-1376天),多数未进一步恶化。
- 这38例中2例发生粒细胞缺乏症并接受急诊甲状腺切除术;发生中性粒细胞减少的患者显著更年轻(p=0.031)。
- 卡比马唑组中性粒细胞减少发生率50%(n=20/40)显著高于甲巯咪唑组16.5%(n=18/110;p=0.001);卡比马唑组最低中性粒细胞绝对值(1971/µL ± 1008)显著低于甲巯咪唑组(2546/µL ± 959);p=0.004。
关键数值与推荐
- 中性粒细胞减少定义为中性粒细胞绝对值<1800/µL。
- 粒细胞缺乏症定义为中性粒细胞绝对值<500/µL。
- 纳入标准:fT4 >25 pmol/L、TSH <0.05 mlU/mL、TSHRAbs >2.5 IU/L。
临床怎么用
- 作者建议儿童Graves病患者应使用甲巯咪唑治疗。
- 作者认为可能需要频繁测量中性粒细胞绝对值以发现严重粒细胞缺乏症。
- 作者指出治疗前中性粒细胞绝对值偏低不一定是对抗甲状腺药物治疗的禁忌。
局限性
- 需要进一步研究以充分了解儿童Graves病患者中性粒细胞减少的危险因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Agranulocytosis is a rare antithyroid drug treatment (ATD) side effect seen in children suffering from Graves' disease (GD). Neutropenia is a recognized adverse event associated with ATD but has also been reported as pre-treatment neutropenia in GD. Methods: We performed a retrospective cohort study to analyze the longitudinal clinical and biochemical data of 161 pediatric patients with GD who received either methimazole (MMI) or carbimazole (CBZ) as ATD. The inclusion criteria were elevated free thyroxine (fT4 >25 pmol/L), suppressed thyrotropin (TSH <0.05 mlU/mL), and elevated thyrotropin receptor antibodies (TSHRAbs >2.5 IU/L). Absolute neutrophil count (ANC) was used to define neutropenia (ANC <1800/µL) and agranulocytosis (ANC <500/µL). Results: Nine of the 161 patients had neutropenia at diagnosis (ANC: 1348/µL ± 250) without further deterioration under ATD. In this subgroup, we found higher levels of free triiodothyronine (fT3: 31.45 pmol/L ± 3.99) at diagnosis in comparison with those who developed neutropenia (26.29 pmol/L ± 12.96; p = 0.07) and those without neutropenia before and during therapy (23.12 pmol/L ± 13.7; p = 0.003). Thirty-eight patients (23.6%) became neutropenic (ANC: 1479/µL ± 262) while receiving ATD. Neutropenia occurred after a mean of 551.8 (range: 10-1376) days, mostly without further deterioration. Two of these 38 patients developed agranulocytosis and underwent emergency thyroidectomy. The patients with neutropenia were significantly younger (p = 0.031). Neutropenia occurred significantly more often in patients receiving CBZ (50%; n = 20/40) than in those receiving MMI (16.5%; n = 18/110; p = 0.001). The minimum ANC was significantly lower in the CBZ (1971/µL ± 1008) than in the MMI group (2546 ± 959); p = 0.004. Conclusions: Neutropenia occurred significantly more often under CBZ than MMI. As this is potentially due to higher immunogenicity, we suggest that children with GD should be treated with MMI. Frequent measurements of ANC may be needed to detect severe agranulocytosis, although low pre-treatment ANC may not necessarily be a contraindication to ATD treatment. Young age may be potentially associated with an increased risk of reduced ANC. Further investigation is necessary to fully understand risk factors for neutropenia in children with GD.
引用
- Schempp V, Cebeci AN, Reinauer C, et al. Neutropenia Occurs More Often Under Carbimazole than Under Methimazole Treatment in Pediatric Graves' Disease Patients. Thyroid. 2024. PMID: 38613811. doi:10.1089/thy.2023.0673
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。